BRPI0411324A - composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes - Google Patents

composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes

Info

Publication number
BRPI0411324A
BRPI0411324A BRPI0411324-1A BRPI0411324A BRPI0411324A BR PI0411324 A BRPI0411324 A BR PI0411324A BR PI0411324 A BRPI0411324 A BR PI0411324A BR PI0411324 A BRPI0411324 A BR PI0411324A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
patients
mediated response
treating histamine
Prior art date
Application number
BRPI0411324-1A
Other languages
English (en)
Inventor
Gilbert R Gonzales
Original Assignee
Pediamed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pediamed Pharmaceuticals Inc filed Critical Pediamed Pharmaceuticals Inc
Publication of BRPI0411324A publication Critical patent/BRPI0411324A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS E MéTODOS DE TRATAMENTO DE RESPOSTA MEDIADA POR HISTAMINA EM PACIENTES". A presente invenção proporciona composições farmacêuticas que incluem uma anti-histamina sedativa e um estimulante e métodos de uso das mesmas. O estimulante reduz a sedação causada pela antihistamina, permitindo, dessa maneira, que anti-histaminas potentes, mas, sedativas sejam usadas com efetividade.
BRPI0411324-1A 2003-06-17 2004-06-16 composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes BRPI0411324A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/463,556 US20040259809A1 (en) 2003-06-17 2003-06-17 Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof
PCT/US2004/018986 WO2004112771A1 (en) 2003-06-17 2004-06-16 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof

Publications (1)

Publication Number Publication Date
BRPI0411324A true BRPI0411324A (pt) 2006-07-25

Family

ID=33517116

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411324-1A BRPI0411324A (pt) 2003-06-17 2004-06-16 composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes

Country Status (8)

Country Link
US (1) US20040259809A1 (pt)
EP (1) EP1641446A1 (pt)
JP (1) JP2007527860A (pt)
AU (1) AU2004249186A1 (pt)
BR (1) BRPI0411324A (pt)
CA (1) CA2528711A1 (pt)
MX (1) MXPA05013758A (pt)
WO (1) WO2004112771A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012506B2 (en) * 2001-04-10 2011-09-06 Pernix Therapeutics, Llc Tannate compositions, methods of making and methods of use
US8257746B2 (en) 2001-04-10 2012-09-04 Pernix Therapeutics, Llc Tannate compositions, methods of making and methods of use
US9592197B2 (en) 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PL2522365T3 (pl) 2004-11-24 2017-05-31 Meda Pharmaceuticals Inc. Kompozycje zawierające azelastynę i sposoby ich zastosowania
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
EP2428205B1 (en) 2006-03-16 2012-10-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
EP2420147B1 (en) * 2010-08-17 2017-05-17 Vitae Natural Nutrition, S.L. Nutritional supplement compositon
WO2012090218A1 (en) 2010-12-30 2012-07-05 Zota Health Care Ltd Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases
US9149474B2 (en) 2011-11-23 2015-10-06 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
US9629847B2 (en) 2011-11-23 2017-04-25 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
EP2906208B1 (en) 2012-10-09 2019-01-30 Sears, Douglas Therapeutic treatment
CN104189011A (zh) * 2014-09-29 2014-12-10 安徽安科恒益药业有限公司 一种小儿氨酚黄那敏颗粒的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1146183A (en) * 1965-07-01 1969-03-19 Stabilimenti Chimico Farmaceut Improvements in or relating to nicotinamide derivatives having an analgesic, anti-inflammatory, antipyretic and anti-histaminic action, method for their preparation, andtherapeutical use
SE335202B (pt) * 1968-06-19 1971-05-17 Aco Laekemedel Ab
US3940485A (en) * 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4466960A (en) * 1983-10-18 1984-08-21 Thompson Medical Co., Inc. Analgesic-diuretic compositions
AU2100795A (en) * 1994-06-06 1996-01-04 Warner-Lambert Company Non-sedating allergy sinus medication
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US5648358A (en) * 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
AU5478699A (en) * 1998-08-13 2000-03-06 Bridge Pharma, Inc. Non-sedating diphenhydramine metabolites

Also Published As

Publication number Publication date
AU2004249186A1 (en) 2004-12-29
JP2007527860A (ja) 2007-10-04
US20040259809A1 (en) 2004-12-23
WO2004112771A8 (en) 2006-02-09
EP1641446A1 (en) 2006-04-05
WO2004112771A1 (en) 2004-12-29
MXPA05013758A (es) 2006-03-13
CA2528711A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
WO2004019884A3 (en) Agents and methods for enhancing bone formation
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
UY28007A1 (es) Tratamiento terapeutico
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired